- Home
- PHAR vs NPKI Comparison
PHAR vs NPKI Comparison
Compare PHAR & NPKI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- NPKI
- Stock Information
- Founded
- PHAR 1988
- NPKI 1932
- Country
- PHAR Netherlands
- NPKI United States
- Employees
- PHAR N/A
- NPKI N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- NPKI Metal Fabrications
- Sector
- PHAR Health Care
- NPKI Industrials
- Exchange
- PHAR Nasdaq
- NPKI Nasdaq
- Market Cap
- PHAR 731.1M
- NPKI 722.7M
- IPO Year
- PHAR N/A
- NPKI N/A
- Fundamental
- Price
- PHAR $10.00
- NPKI $8.55
- Analyst Decision
- PHAR Strong Buy
- NPKI Strong Buy
- Analyst Count
- PHAR 3
- NPKI 1
- Target Price
- PHAR $30.00
- NPKI $12.00
- AVG Volume (30 Days)
- PHAR 3.6K
- NPKI 790.3K
- Earning Date
- PHAR 07-31-2025
- NPKI 08-04-2025
- Dividend Yield
- PHAR N/A
- NPKI N/A
- EPS Growth
- PHAR N/A
- NPKI N/A
- EPS
- PHAR N/A
- NPKI N/A
- Revenue
- PHAR $320,708,000.00
- NPKI $233,299,000.00
- Revenue This Year
- PHAR $13.31
- NPKI $15.28
- Revenue Next Year
- PHAR $7.68
- NPKI $9.62
- P/E Ratio
- PHAR N/A
- NPKI $17.71
- Revenue Growth
- PHAR 24.13
- NPKI 312.30
- 52 Week Low
- PHAR $6.65
- NPKI $4.76
- 52 Week High
- PHAR $12.61
- NPKI $8.88
- Technical
- Relative Strength Index (RSI)
- PHAR 43.61
- NPKI N/A
- Support Level
- PHAR $9.99
- NPKI N/A
- Resistance Level
- PHAR $10.59
- NPKI N/A
- Average True Range (ATR)
- PHAR 0.35
- NPKI 0.00
- MACD
- PHAR -0.14
- NPKI 0.00
- Stochastic Oscillator
- PHAR 7.45
- NPKI 0.00
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About NPKI NPK International Inc. Common Stock
NPK International Inc is a temporary worksite access solutions company that manufactures, sells, and rents recyclable composite matting products, along with a full suite of services, including planning, logistics, and site restoration. The company generates majority of revenue from the rental of recyclable composite matting systems, along with related site construction and services to customers in various markets including power transmission, oil and natural gas exploration and production, pipeline, renewable energy, petrochemical, construction and other industries within the United States and United Kingdom.